Latest news
Weekly Recap: September 2026 seralutinib NDA and $115.9M debt cut - TradingViewTradingView · Mon, 03 Aug 2026 11:33:04 GMTGossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update - Yahoo FinanceYahoo Finance · Fri, 31 Jul 2026 07:00:00 GMTGossamer Bio Plans September 2026 Seralutinib NDA After FDA Meeting - Quiver QuantitativeQuiver Quantitative · Mon, 27 Jul 2026 20:57:00 GMT